

**Exhibit 2157**  
**Materials Considered by Dr. Michael A. Gorin, M.D.**

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                  |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>1001</b>        | U.S. Patent No. 10,980,901 (“the ‘901 patent”)                                                                                                                                                                                      |
| <b>1002</b>        | Declaration of Dr. Michael Zalutsky, and cited references (Exhibits 1001, 1004-1044)                                                                                                                                                |
| <b>1003</b>        | Curriculum Vitae of Dr. Michael Zalutsky, Ph.D.                                                                                                                                                                                     |
| <b>1004</b>        | File History of U.S. Patent No. 10,980,901                                                                                                                                                                                          |
| <b>1005</b>        | Marc A. Bjurlin, et al., <i>Imaging and evaluation of patients with high-risk prostate cancer</i> , 12 Nature Reviews Urology 617 (2015) (“Bjurlin”).                                                                               |
| <b>1006</b>        | Kristell Chatalic, et al., <i><sup>213</sup>Bi-labeled PSMA-targeting agents for alpha radionuclide therapy of prostate cancer</i> , 57 J. Nuclear Med. 137 (2016) (“Chatalic”).                                                    |
| <b>1007</b>        | Emre Demirci, <i><sup>68</sup>Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma</i> , 41 Eur. J. Nuclear Med. Molecular Imaging 1461 (2014) (“Demirci”).                                                         |
| <b>1008</b>        | Catherine A. Foss, et al., <i>Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer</i> , 11 Clinical Cancer Rsch. 4022 (2005) (“Foss”).            |
| <b>1009</b>        | Shawn Hillier, et al., <i>[<sup>131</sup>I] MIP-1375, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted therapy of prostate cancer (PCa)</i> , 52 J. Nuclear Med. 361 (2011) (“Hillier 2011”).      |
| <b>1010</b>        | Shawn Hillier, et al., <i>[<sup>131</sup>I] MIP-1466, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted radiotherapy of prostate cancer (PCa)</i> , 53 J. Nuclear Med. 170 (2012) (“Hillier 2012”). |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                       |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>1011</b>        | Joseph G. Jurcic, et. al., <i>Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (<sup>225</sup>Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older</i>                                            |
| <b>1012</b>        | Susan J. Mandel, et al., <i>Superiority of Iodine-123 Compared with Iodine-131 Scanning for Thyroid Remnants in Patients with Differentiated Thyroid Cancer</i> , 26 Clinical Nuclear Med. 6 (2001) (“Mandel”).                          |
| <b>1013</b>        | Michael R. McDevitt, et al., <i>Tumor Therapy with Targeted Atomic Nanogenerators</i> , 294 Science 1537 (2001) (“McDevitt 2001”).                                                                                                       |
| <b>1014</b>        | Michael R. McDevitt, et al., <i>Design and synthesis of <sup>225</sup>Ac radioimmunopharmaceuticals</i> , 57 Applied Radiation & Isotopes 841 (2002) (“McDevitt 2002”).                                                                  |
| <b>1015</b>        | Matthias Miederer, et al., <i>Preclinical Evaluation of the α-Particle Generator Nuclide <sup>225</sup>Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors</i> , 14 Clinical Cancer Rsch. 3555 (2008) (“Miederer 2008a”). |
| <b>1016</b>        | Dianne E. Milenic & Martin W. Brechbiel, <i>Targeting of Radio-Isotopes for Cancer Therapy</i> , 3 Cancer Biology & Therapy 361 (2004) (“Milenic”).                                                                                      |
| <b>1017</b>        | George Sgourous, et al., <i>MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy</i> , 51 J. Nuclear Med. 311 (2010) (“MIRD Pamphlet”).                                  |
| <b>1018</b>        | Natsuko Normura, et al., <i>Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases</i> , 14 Cancer Cell Int'l 1 (2014) (“Nomura”).                                                   |
| <b>1019</b>        | Martin G. Pomper, et al., <i><sup>11</sup>C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase)</i> , 1 Molecular Imaging 96 (2002) (“Pomper”).                                 |
| <b>1020</b>        | Justin R. Hubenak, et al., <i>Mechanisms of injury to normal tissue after radiotherapy: a review</i> , 133 Plastic Reconstructive Surgery 49 (2014) (“Hubenak”).                                                                         |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                             |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>1021</b>        | Jeffery S. Ross, et al., <i>Correlation of Primary Tumor Prostate-Specific Membrane Antigen Expression with Disease Recurrence in Prostate Cancer</i> , 9 Clinical Cancer Rsch. 6357 (2003) (“Ross”).                                          |
| <b>1022</b>        | David A. Scheinberg & Michael R. McDevitt, <i>Actinium-225 in targeted alpha-particle therapeutic applications</i> , 4 Current Radiopharmaceuticals 306 (2011) (“Scheinberg”).                                                                 |
| <b>1023</b>        | David A. Silver, et al., <i>Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues</i> , 3 Clinical Cancer Rsch. 81 (1997) (“Silver”).                                                                            |
| <b>1024</b>        | Baris Turkbey, et al., <i>Multiparametric Prostate Magnetic Resonance Imaging in the Evaluation of Prostate Cancer</i> , 66 CA: Cancer J. for Clinicians 326 (2016) (“Turkbey”).                                                               |
| <b>1025</b>        | U.S. Patent No. 10,471,160 (“the ‘160 patent”).                                                                                                                                                                                                |
| <b>1026</b>        | U.S. Patent No. 10,398,791 (“the ‘791 patent”).                                                                                                                                                                                                |
| <b>1027</b>        | Martina Weineisen, et al., <i>Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer</i> , 4 EJNMMI Rsch. 1 (2014) (“Weineisen 2014”).                          |
| <b>1028</b>        | Martina Weineisen, et al., <i><sup>68</sup>Ga-and <sup>177</sup>Lu-labeled PSMA I&amp;T. Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies</i> , 56 J. Nuclear Med. 1169 (2015) (“Weineisen 2015”). |
| <b>1029</b>        | Alla G. Wernicke, et al., <i>Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers</i> , 122 APMIS 482 (2014) (“Wernicke”).                                                                          |
| <b>1030</b>        | Matthias Miederer, et al., <i>Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications</i> , 60 Advanced Drug Delivery Revs. 1371 (2008) (“Miederer 2008b”).                         |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                                                                                |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>1031</b>        | Clemens Kratochwil, et al., <i>Ac-225-DOTATOC - an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors</i> , 56 J. Nuclear Med. 1232 (2015) (“Kratochwil”).                                                                                       |
| <b>1032</b>        | Randall D. Knight, <i>Physics For Scientists and Engineers</i> 1369–70 (Adam Black et al. eds., vol. 5 2005) (“Knight”).                                                                                                                                                                          |
| <b>1033</b>        | Liang Zhao, et al., <i>Clinical pharmacology considerations in biologics development</i> , 33 Acta Pharmacologica Sinica 1339 (2012) (“Zhao”).                                                                                                                                                    |
| <b>1034</b>        | U.S. Dep’t Health & Hum. Servs., <i>Anthropometric Reference Data for Children and Adults: United States, 2015–2018 Series 3</i> , 9 (2021) (“HHS”).                                                                                                                                              |
| <b>1035</b>        | Nerissa Viola-Villegas & Robert P. Doyle, <i>The coordination chemistry of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (H4DOTA): Structural overview and analyses on structure–stability relationships</i> , 253 Coordination Chemistry Reviews 1906 (2009) (“Viola-Villegas”). |
| <b>1036</b>        | Nima Sharifi, et al., <i>Androgen Deprivation Therapy for Prostate Cancer</i> , 294 JAMA 238 (2005) (“Sharifi”).                                                                                                                                                                                  |
| <b>1037</b>        | Nat’l Cancer Inst., <i>SEER Cancer Stat Facts: Prostate Cancer</i> , seer.cancer.gov, <a href="https://seer.cancer.gov/statfacts/html/prost.html">https://seer.cancer.gov/statfacts/html/prost.html</a> (last visited Jan. 31, 2023) (“NCI”).                                                     |
| <b>1038</b>        | Sharmila Banerjee, et al., <i>Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications</i> , 115 Chem. Revs. 2934 (2015) (“Banerjee”).                                                                                                        |
| <b>1039</b>        | Arundhati Ghosh & Warren D.W. Heston, <i>Tumor Target Prostate Specific Membrane Antigen (PSMA) and its Regulation in Prostate Cancer</i> , 91 J. Cellular Biochemistry 528 (2004) (“Ghosh”).                                                                                                     |
| <b>1040</b>        | Declaration of Dr. Rebecca Abergel, Ph.D.                                                                                                                                                                                                                                                         |
| <b>1041</b>        | Eric W. Price and Chris Orvig, <i>Matching chelators to radiometals for radiopharmaceuticals</i> , 43 Chem. Soc. Rev. 260-290 (2014) (“Price”).                                                                                                                                                   |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                                        |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>1042</b>        | Kristell L.S. Chatalic, et al., <i>Towards Personalized Treatment of Prostate Cancer: PSMA I&amp;T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent</i> , 6(6) <i>Theranostics</i> , 849-861 (2016) (“Chatalic 2016b”)          |
| <b>1043</b>        | Robin M. de Kruijff, et al., <i>A Critical Review of Alpha Radionuclide Therapy – How to Deal with Recoiling Daughters?</i> , 8 <i>Pharmaceuticals</i> , 321-336 (2015) (“de Kruijff”)                                                                    |
| <b>1044</b>        | Declaration of Dr. Thomas Hope, M.D.                                                                                                                                                                                                                      |
| <b>1045</b>        | Kratochwil et al., “225 Ac-PSMA-617 for PSMA-Targeted $\alpha$ -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer,” <i>Journal of Nuclear Medicine</i> , vol. 57, no. 12, pgs. 1941-1944 (2016) (Kratochwil 2016)                      |
| <b>1046</b>        | Xofigo® FDA label packaging insert (revised May 2013)                                                                                                                                                                                                     |
| <b>2070</b>        | Center MM, et al., International variation in prostate cancer incidence and mortality rates. <i>Eur Urol.</i> 2012;61(6):1079–92                                                                                                                          |
| <b>2071</b>        | Bidkar, AP, et al., Actinium-225 targeted alpha particle therapy for prostate cancer, <i>Theranostics</i> 2024 14(7):2969-2992.                                                                                                                           |
| <b>2072</b>        | Miederer, M, et al., Pharmacokinetics, Dosimetry, and Toxicity of the Targetable Atomic Generator, 225Ac-HuM195, in Nonhuman Primates, <i>J Nucl. Med.</i> 2004; 45:129–137                                                                               |
| <b>2073</b>        | Declaration by Dr. Morgenstern                                                                                                                                                                                                                            |
| <b>2074</b>        | The Journal of Nuclear Medicine, About the Cover, December 1, 2016, Vol. 57, Issue 12, <a href="https://jnm.snmjournals.org/content/57/12.cover-expansion">https://jnm.snmjournals.org/content/57/12.cover-expansion</a> (last visited November 21, 2023) |
| <b>2075</b>        | U.S. Patent No. 10,471,160 (the “160 Patent”)                                                                                                                                                                                                             |
| <b>2076</b>        | Declaration by Dr. Kratochwil                                                                                                                                                                                                                             |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                                                                                                                                                                                                         |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>2077</b>        | Declaration by Dr. Kopka                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>2078</b>        | Benešová, M, <i>et al.</i> , Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer, <i>J Nucl Med.</i> 2015; 56:914–920                                                                                                                                                                                                  |
| <b>2079</b>        | U.S. Patent No. 10,398,791                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>2080</b>        | Deposition Testimony of Dr. Rebecca Abergel, Ph.D.                                                                                                                                                                                                                                                                                                                                                                         |
| <b>2081</b>        | NCT04597411: Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer<br><a href="https://www.clinicaltrials.gov/study/NCT04597411">https://www.clinicaltrials.gov/study/NCT04597411</a><br>(last visited 11/16/2025)                                                                                                                                                                                             |
| <b>2082</b>        | NCT07054346: Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 (LUTACT)<br><a href="https://www.clinicaltrials.gov/study/NCT07054346?term=NCT07054346&amp;rank=1">https://www.clinicaltrials.gov/study/NCT07054346?term=NCT07054346&amp;rank=1</a><br>(last visited 11/16/2025)                                                                                                                                              |
| <b>2083</b>        | NCT07150715: Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma (ANDROMEDA)<br><a href="https://www.clinicaltrials.gov/study/NCT07150715?term=NCT07150715&amp;rank=1">https://www.clinicaltrials.gov/study/NCT07150715?term=NCT07150715&amp;rank=1</a><br>(last visited 11/16/2025) |
| <b>2084</b>        | NCT06855277: Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (AcTFirst)<br><a href="https://www.clinicaltrials.gov/study/NCT06855277?term=NCT06855277&amp;rank=1">https://www.clinicaltrials.gov/study/NCT06855277?term=NCT06855277&amp;rank=1</a><br>(last visited 11/16/2025)                                                                                         |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>2085</b>        | <p>NCT06780670: Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy (PSMAcTION)</p> <p><a href="https://www.clinicaltrials.gov/study/NCT06780670?term=NCT06780670&amp;rank=1">https://www.clinicaltrials.gov/study/NCT06780670?term=NCT06780670&amp;rank=1</a><br/>(last visited 11/16/2025)</p> |
| <b>2086</b>        | <p>NCT06909825: FPI-2265 (225Ac-PSMA-I&amp;T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)</p> <p><a href="https://www.clinicaltrials.gov/study/NCT06909825?term=NCT06909825&amp;rank=1">https://www.clinicaltrials.gov/study/NCT06909825?term=NCT06909825&amp;rank=1</a><br/>(last visited 11/16/2025)</p>                                                                                            |
| <b>2087</b>        | <p>NCT06402331: FPI-2265 (225Ac-PSMA-I&amp;T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (AlphaBreak)</p> <p><a href="https://www.clinicaltrials.gov/study/NCT06402331?term=NCT06402331&amp;rank=1">https://www.clinicaltrials.gov/study/NCT06402331?term=NCT06402331&amp;rank=1</a><br/>(last visited 11/16/2025)</p>                                                                              |
| <b>2088</b>        | <p>NCT05219500: Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&amp;T of Castration-resistant Prostate Cancer (TATCIST). (TATCIST)</p> <p><a href="https://www.clinicaltrials.gov/study/NCT05219500?term=NCT05219500&amp;rank=1">https://www.clinicaltrials.gov/study/NCT05219500?term=NCT05219500&amp;rank=1</a><br/>(last visited 11/16/2025)</p>                                                          |
| <b>2089</b>        | <p>NCT05902247: Actium-225-Prostate Specific Membrane Antigen Imaging &amp; Therapy (225AcPSMAI&amp;T)</p> <p><a href="https://www.clinicaltrials.gov/study/NCT05902247?term=NCT05902247&amp;rank=1">https://www.clinicaltrials.gov/study/NCT05902247?term=NCT05902247&amp;rank=1</a><br/>(last visited 11/18/2025)</p>                                                                                                                          |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>2090</b>        | Max Beauroyre, <i>Clinical-Trial Costing 101: Building a Phase-By-Phase Budget Your Board Will Trust</i> , Abacum (June 25,2025), <a href="https://www.abacum.ai/blog/clinical-trial-costing">https://www.abacum.ai/blog/clinical-trial-costing</a> (last visited 11/16/2025)                                                                                                                                                                                                                                                                                                 |
| <b>2091</b>        | Certified Clinical Rsch. Pros. Soc’y (CCRPS), <i>Phase III Clinical Trials: Definitive Guide &amp; Case Studies</i> (June 8, 2025), <a href="https://ccrps.org/clinical-research-blog/phase-iii-clinicaltrials-definitive-guide-amp-case-studies#:~:text=Why%20are%20Phase%20III%20trials,costly%20phase%20in%20drug%20development">https://ccrps.org/clinical-research-blog/phase-iii-clinicaltrials-definitive-guide-amp-case-studies#:~:text=Why%20are%20Phase%20III%20trials,costly%20phase%20in%20drug%20development</a> (last visited 11/16/2025)                       |
| <b>2092</b>        | Sertkaya, A. <i>et. al.</i> , Costs of Drug Development and Research and Development Intensity in the US, 2000-2018. <i>JAMA Network</i> 2024;7(6):e2415445                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>2093</b>        | Calais, J. et al., Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer, <i>Cancer Treat. Rev</i> 2023;115:102524                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>2094</b>        | Google data for Kratochwil, et al, 225Ac-PSMA-617 for PSMA-targeted $\alpha$ -radiation therapy of metastatic castration-resistant prostate cancer, <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C34&amp;q=225+Ac-PSMA-617+for+PSMA-Targeted+%CE%B1-Radiation+Therapy+of+Metastatic+Castration-Resistant+Prostate+Cancer&amp;btnG=">https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C34&amp;q=225+Ac-PSMA-617+for+PSMA-Targeted+%CE%B1-Radiation+Therapy+of+Metastatic+Castration-Resistant+Prostate+Cancer&amp;btnG=</a> (last visited 10/21/2025) |
| <b>2095</b>        | Altmetric data for Kratochwil, et al, 225Ac-PSMA-617 for PSMA-targeted $\alpha$ -radiation therapy of metastatic castration-resistant prostate cancer, <a href="https://www.altmetric.com/details/9534712#score">https://www.altmetric.com/details/9534712#score</a> (last visited 10/21/2025)                                                                                                                                                                                                                                                                                |
| <b>2096</b>        | U.S. Patent Application Publication No. 2025/0303004 A1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                                                                                       |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>2097</b>        | Kratochwil, C, <i>et al.</i> , Targeted $\alpha$ -Therapy of Metastatic Castration-Resistant Prostate Cancer with $^{225}\text{Ac}$ -PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control, <i>J Nucl Med.</i> 2018 May;59(5):795-802.                                   |
| <b>2098</b>        | Sathekge, M, <i>et al.</i> , Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving $^{225}\text{Ac}$ -PSMA-617 Radioligand Therapy, <i>J Nucl Med.</i> 2020 Jan;61(1):62-69.                                                             |
| <b>2099</b>        | Rathke, H, <i>et al.</i> , First patient exceeding 5-year complete remission after $^{225}\text{Ac}$ -PSMA-TAT, <i>European Journal of Nuclear Medicine and Molecular Imaging</i> (2021) 48:311–312.                                                                                                     |
| <b>2100</b>        | Kratochwil, C, <i>et al.</i> , Patients Resistant Against PSMA-Targeting $\alpha$ -Radiation Therapy Often Harbor Mutations in DNA Damage-Repair–Associated Genes, <i>J Nucl Med.</i> 2020; 61:683–688                                                                                                   |
| <b>2101</b>        | Kratochwil, C, <i>et al.</i> , Targeted $\alpha$ -Therapy of Metastatic Castration-Resistant Prostate Cancer with $^{225}\text{Ac}$ -PSMA-617: Dosimetry Estimate and Empiric Dose Finding, <i>J Nucl Med.</i> 2017 Oct;58(10):1624-1631. (“Kratochwil 2017”)                                            |
| <b>2102</b>        | van der Doelen, MJ, <i>et al.</i> , Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with $^{225}\text{Ac}$ -PSMA-617 targeted alpha-radiation therapy, <i>Urologic Oncology</i> (2021) 39:729.e7–729.e16                          |
| <b>2103</b>        | Curium BidCo S.a.r.l. Consolidated Financial Statements and Consolidated Management Report for the Year Ended December 31, 2023                                                                                                                                                                          |
| <b>2104</b>        | Curium Locations<br><a href="https://www.dnb.com/business-directory/company-profiles.curium_us_holdings_llc.6eed735ca84fb91650ac6a1d54ecee08.html">https://www.dnb.com/business-directory/company-profiles.curium_us_holdings_llc.6eed735ca84fb91650ac6a1d54ecee08.html</a><br>(last visited 11/12/2025) |
| <b>2105</b>        | Curium US Holdings LLC Notice of Reorganization Closing and Name Change Notification for Curium US PET LLC                                                                                                                                                                                               |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                                                                                                                                           |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>2106</b>        | Curium US Holdings LLC Application for Approval of Transfer of Control                                                                                                                                                                                                                                                                                       |
| <b>2107</b>        | Curium: What we do<br><a href="https://www.curiumpharma.com/about/what-we-do/#:~:text=We%20specialize%20in%20the%20production,treatment%20and%20proven%20patient%20outcomes.">https://www.curiumpharma.com/about/what-we-do/#:~:text=We%20specialize%20in%20the%20production,treatment%20and%20proven%20patient%20outcomes.</a><br>(last visited 11/12/2025) |
| <b>2108</b>        | Feng, Y., et. al. A Third Generation PSMA-targeted Agent [211At]YF2: Synthesis and In Vivo Evaluation, <i>Nucl. Med. Biol.</i> 2024:134-135 (“Feng”)                                                                                                                                                                                                         |
| <b>2109</b>        | Curriculum Vitae of Dr. Thomas A. Hope, M.D. prepared 11/11/2023                                                                                                                                                                                                                                                                                             |
| <b>2110</b>        | Cimons et al., “Cancer Drugs Face Long Road From Mice to Men,” Los Angeles Times, <a href="https://www.latimes.com/archives/la-xpm-1998-may-06-mn-46795-story.html">https://www.latimes.com/archives/la-xpm-1998-may-06-mn-46795-story.html</a> (1998).                                                                                                      |
| <b>2111</b>        | Denison, TA et al, Tumor Heterogeneity and its Implication to Drug Delivery, <i>J Control Release</i> 2012 December 10; 164(2): 187-191.doi:10.1016/j.jconrel.2012.04.014. (“Denison”)                                                                                                                                                                       |
| <b>2112</b>        | Turner, PG, et al. <sup>223</sup> Ra and other bone-targeting radiopharmaceuticals—the translation of radiation biology into clinical practice. <i>Fr. J. Radiol</i> 2015;88:20140752 at 5. (“Turner”)                                                                                                                                                       |
| <b>2113</b>        | Abou, DS, <i>et al.</i> , Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis, <i>J Natl Cancer Inst</i> 2016; 108(5): djv380                                                                                                                                                               |
| <b>2114</b>        | DeBlonde, GJ, Abergel, RJ, “Active Actinium,” <i>Nat Chem.</i> , vol. 8, no. 11, pg. 1084 (November 2016) (“Abergel 2016”)                                                                                                                                                                                                                                   |
| <b>2115</b>        | Pallares RM and Abergel RJ, Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand? <i>Front. Med.</i> 2022; 9:1020188 (“Abergel 2022”)                                                                                                                                                                                           |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                                                                    |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>2116</b>        | Burnett, AK, et al, A Comparison of Low Dose Cytarabine and Hydroxyurea With or Without All trans Retinoic Acid for Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome in Patients Not Considered Fit for Intensive Treatment, <i>Cancer</i> 2007; 109:1114-24 (“Burnett”) |
| <b>2117</b>        | Winter, JN, et al., Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. <i>Cancer</i> 1985; 56(3):443-9 (“Winter”)                                                                                                                     |
| <b>2118</b>        | Tilly, H, et al., Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients, <i>Cancer</i> 1985; 55(8):1633-6 (“Tilly”)                                                                                                                           |
| <b>2119</b>        | Cheson, BD, et al., A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes, <i>J Clin Oncol</i> 1986; 4(12):1857-64 (“Cheson”)                                                                           |
| <b>2120</b>        | Lin M, et al., Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives, <i>Cancer Biother Radiopharm</i> 2021 Apr;36(3):237-251 (“Lin”)                                                  |
| <b>2121</b>        | Morton, JJ, et al. Humanized mouse xenograft models: narrowing the tumor-microenvironment gap, <i>Cancer Res.</i> 2016; 76(21): 6153–6158 (“Morton”)                                                                                                                                  |
| <b>2122</b>        | Zacherl, MT, et al., First Clinical Results for PSMA-Targeted α-Therapy Using <sup>225</sup> Ac-PSMA-I&T in Advanced-mCRPC Patients, <i>J. Nucl. Med.</i> 2021; 62:669-674 (“Zacherl”)                                                                                                |
| <b>2123</b>        | Fanti, S, et al. Highlights of the 30th Annual Congress of the EANM, Vienna 2017: “Yes we can – make nuclear medicine great again,” <i>Eur. J. Nuc. Med. Mol. Im.</i> 2018; 45:1781–1794 (“Fanti”)                                                                                    |
| <b>2124</b>        | <a href="https://www.eanm.org/congresses-events/awards-grants/winners/">https://www.eanm.org/congresses-events/awards-grants/winners/</a>                                                                                                                                             |
| <b>2125</b>        | Nonnekens, J., et al., <sup>213</sup> Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-StrandBreaks in Prostate Cancer Xenografts, <i>Canc. Bioth. Rad.</i> 2017, 32 (2), 67-73 (“Nonnekens”)                                                         |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                                     |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>2126</b>        | Alam, MR, et al., A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer, <i>Cureus</i> 2022; 14(9): e29369 (“Alam”)                                                                                      |
| <b>2127</b>        | Feuerecker, B., et al., Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution? <i>J Nucl Med</i> 2023; 64:685–692 (“Feuerecker”)                                                                                                    |
| <b>2128</b>        | Lepareur, N. An overview of current phase 3 radiopharmaceutical therapy clinical trials <i>Front. Med.</i> 2025 12:1549676. (“Lepareur”)                                                                                                               |
| <b>2129</b>        | Jalloul, W., <i>et al.</i> Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management <i>Pharmaceuticals</i> <b>2025</b> , 18, 1215 (“Jalloul”) |
| <b>2130</b>        | Munekane, M, et. al., Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics, <i>Anal. Sci.</i> <b>2024</b> 40:803-826. (“Munekane”)                                                                        |
| <b>2131</b>        | PubMed results: Ex. 1045 Kratochwil 2016 last visited October 21, 2025                                                                                                                                                                                 |
| <b>2132</b>        | PubMed results: Ex. 1028: Weineisen 2015 last visited October 21, 2025                                                                                                                                                                                 |
| <b>2133</b>        | Google Scholar results: Ex. 1028: Weineisen 2015 last visited October 21, 2025                                                                                                                                                                         |
| <b>2134</b>        | Zalutsky, MR and Pruszyński, M, Astatine-211: production and availability. <i>Current radiopharmaceuticals</i> 2011;4(3):177-185.                                                                                                                      |
| <b>2135</b>        | Nordstrom, M. <i>et al</i> , Identification of plasma protein profiles associated with risk groups of prostate cancer patients, <i>Proteomics Clin. Appl.</i> 2014 December; 8(0): 951-962 (“Nordstrom”)                                               |
| <b>2136</b>        | Afshar-Oromieh, A., <i>et al</i> , The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer, <i>J. Nucl. Med.</i> 2016; 57:79S-89S, DOI: 10.2967/jnumed.115.170720 (“Afshar-Oromieh”)                                                     |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                                                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>2137</b>        | Berney, DM <i>et al</i> , Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome, <i>British Journal of Cancer</i> (2016) 114, 1078-1083, doi: 10.1038/bjc.2016.86 (“Berney”)                                                            |
| <b>2139</b>        | Deposition testimony of Dr. Michael Zalutsky                                                                                                                                                                                                                                         |
| <b>2158</b>        | Kiess, et al. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl) Ureido)-Pentanedioic Acid for PSMA-Targeted $\alpha$ -Particle, <i>J Nucl Med</i> 2016; 57:1569–1575                                                                                                           |
| <b>2159</b>        | Vallabhajosula et al., Prediction of Myelotoxicity Based on Bone Marrow Radiation-Absorbed Dose: Radioimmunotherapy Studies Using 90Y- and 177Lu-Labeled J591 Antibodies Specific for Prostate-Specific Membrane Antigen, <i>J. Nucl. Med.</i> , Vol, 46, No. 5, pgs. 850-858 (2005) |
| <b>2160</b>        | Cloutier, et al., MIRD Pamphlet No. 21, Dose Estimate Report No. 2, “Summary of Current Radiation Dose Estimates to Humans from 66Ga-, 67Ga-, 68Ga-, and 72Ga-citrate,” <i>J. Nucl. Med.</i> , vol. 14, no. 10, pgs. 755-756 (1973).                                                 |
| <b>2161</b>        | Jaggi, SJ, et al. Efforts to Control the Errant Products of a Targeted In vivo Generator, <i>Cancer Res.</i> 2005; 65: (11)                                                                                                                                                          |
| <b>2162</b>        | Forrer, F, et al., Treatment with 177Lu-DOTATOC of Patients with Relapse of Neuroendocrine Tumors After treatment with 90Y-DOTATOC, <i>J Nucl Med.</i> 2005; 46:1310–1316                                                                                                            |
| <b>2163</b>        | Dorso, L, et al., Long-Term Toxicity of 213Bi-Labelled BSA in Mice, <i>PLOS ONE</i> 2016; 11(3), e0151330                                                                                                                                                                            |
| <b>2164</b>        | Common Terminology Criteria for Adverse Events (CTCAE), V. 5.0, November 27, 2017, U.S. Dept. Health & Human Services.                                                                                                                                                               |
| <b>2165</b>        | Sathekge, M. , et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study <i>Lanc. Onc.</i> , 25 (2), 2024, p. 175-183.                                                                        |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                                          |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>2166</b>        | Ex. 1027: Weineisen 2014 Pubmed                                                                                                                                                                                                                             |
| <b>2167</b>        | Ex. 1027: Weineisen 2014 Google                                                                                                                                                                                                                             |
| <b>2168</b>        | Ex. 1006: Chatalic Google                                                                                                                                                                                                                                   |
| <b>2169</b>        | Ex. 1015: Miederer Pubmed                                                                                                                                                                                                                                   |
| <b>2170</b>        | Ex. 1015: Miederer Google                                                                                                                                                                                                                                   |
| <b>2171</b>        | Ex. 1011: Jurcic Google                                                                                                                                                                                                                                     |
| <b>2172</b>        | Ex. 1031: Kratochwil Google                                                                                                                                                                                                                                 |
| <b>2173</b>        | Afshar-Oromieh et al., The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions, <i>J. Nucl. Med.</i> , vol. 56, no. 11, 1697-1705 (2015). |
| <b>2174</b>        | Schwartz et al., Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody, <i>Phys. Med. Biol.</i> Vol. 56, no. 3, pgs. 721-733 (2011).                                          |
| <b>2175</b>        | Tagawa ST, et al., Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer, <i>Cancer</i> 2010, 116(4 Suppl):1075-83.                                                                                                          |
| <b>2176</b>        | Tagawa ST, et al., Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 in men with metastatic castration-resistant prostate cancer, <i>Front Oncol</i> 2013, 26:3:214  |
| <b>2177</b>        | Tagawa ST, et al., Prostate-Specific Membrane Antigen- Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591, <i>J Clin Oncol</i> 2023, 3:JCO2300573             |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                                                                             |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>2178</b>        | Zalutsky et al., Clinical experience with alpha-particle emitting <sup>211</sup> At: treatment of recurrent brain tumor patients with <sup>211</sup> At-labeled chimeric antitenascin monoclonal antibody 81C6, <i>J. Nucl. Med.</i> Vol. 49, no. 1, pgs. 30-38 (2008)                         |
| <b>2179</b>        | Abbas et al., Experimental $\alpha$ -particle radioimmunotherapy of breast cancer using <sup>227</sup> Th-labeled p-benzyl- DOTA-trastuzumab, <i>EJNMMI Res.</i> Vol. 1, no. 1, pg.18 (2011)                                                                                                   |
| <b>2180</b>        | Parker et al., Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, <i>N. Engl. J. Med.</i> Vol 369, no. 3, pgs. 213-223                                                                                                                                                       |
| <b>2181</b>        | Meredith et al., Dose escalation and dosimetry of first-in-human $\alpha$ radioimmunotherapy with <sup>212</sup> Pb-TCMC-trastuzumab, <i>J. Nucl. Med.</i> , vol. 55, no. 10, pgs. 1636-1642 (2014)                                                                                            |
| <b>2182</b>        | Cordier et al., Targeted alpha- radionuclide therapy of functionally critically located gliomas with <sup>213</sup> Bi-DOTA- [Thi8, Met(O2)11]- substance P: a pilot trial, <i>Eur. J. Nucl. Med. Mol. Imaging</i> , vol. 37, no. 7, pgs. 1335-1344 (2010)                                     |
| <b>2183</b>        | Müller et al., A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for $\alpha$ - and $\beta$ - radionuclide therapy: an in vivo proof-of- concept study with a new receptor-targeted folate derivative, <i>J. Nucl. Med.</i> , vol. 53, no. 12, pgs. 1951-1959 (2012). |
| <b>2184</b>        | Pimm et al, Blood and tissue kinetics of radiolabelled anti-CEA monoclonal antibody and F(ab)2 and Fab fragments in nude mice with human tumour xenografts: implications for tumour imaging and radioimmunotherapy, <i>Nucl. Med. Commun.</i> , vol. 10, no. 8, pgs. 585-593 (1989)            |
| <b>2185</b>        | Sathekge, M., et al., <sup>225</sup> Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study, <i>Eur J Nucl Med Mol Imaging</i> 2019, 46:129–138                                                                                                               |

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                        |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>2186</b>        | Alan-Selcuk, N. <i>et al.</i> , Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer, <i>J Nucl Med</i> 2023 Oct;64(10):1574-1580 |
| <b>2187</b>        | Kauffman, N. <i>et al.</i> , Intra-Arterial Delivery of Radiopharmaceuticals in Oncology: Current Trends and the Future of Alpha-Particle Therapeutics, <i>Pharmaceutics</i> 2023 Apr; 15(4):1138                         |
| <b>2188</b>        | Okamoto, S. <i>et al.</i> , Clinical Perspectives of Theranostics, <i>Molecules</i> 2021 Apr; 26(8):2232                                                                                                                  |
| <b>2189</b>        | Oyen, W.J. and de Bono, J.S., Targeted $\alpha$ -Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?, <i>J Nucl Med</i> 2016 Dec; 57(12): 1838-1839                |